share_log

Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

SEC announcement ·  Feb 26 23:45
Summary by Futu AI
Vertex Pharmaceuticals Inc. officer, Atkinson Edward Morrow III, is set to sell 883 shares of common stock on 02/26/2024, as per the latest filing. The shares, valued at an aggregate market value of $375,893.1, were acquired on 02/24/2024 as performance shares, a form of compensation from the issuer. This transaction follows a series of sales over the past three months, where Morrow sold a total of 2,915 shares, amounting to gross proceeds of $1,227,277.68. The planned sale is in line with a notice dated 02/26/2024, with the original plan adopted on 08/22/2023.
Vertex Pharmaceuticals Inc. officer, Atkinson Edward Morrow III, is set to sell 883 shares of common stock on 02/26/2024, as per the latest filing. The shares, valued at an aggregate market value of $375,893.1, were acquired on 02/24/2024 as performance shares, a form of compensation from the issuer. This transaction follows a series of sales over the past three months, where Morrow sold a total of 2,915 shares, amounting to gross proceeds of $1,227,277.68. The planned sale is in line with a notice dated 02/26/2024, with the original plan adopted on 08/22/2023.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.